NCT05023655View on ClinicalTrials.gov

Phase II Study of Tazemetostat in Solid Tumors Harboring an ARID1A Mutation

PHASE2RecruitingINTERVENTIONAL

Enrollment

40

Participants

Timeline

Start Date

January 6, 2022

Primary Completion Date

January 31, 2027

Study Completion Date

January 31, 2028

Conditions

Solid TumorARID1A Gene Mutation

Interventions

DRUG

Tazemetostat

800mg po twice daily

Trial Locations (1)

29605

RECRUITING

Prisma Health Cancer Institute, Greenville

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

Ipsen

INDUSTRY

lead

Prisma Health-Upstate

OTHER